Home » Stocks » Chimerix

Chimerix, Inc. (CMRX)

Stock Price: $2.89 USD -0.04 (-1.37%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.92 +0.03 (1.04%) Aug 14, 5:09 PM

Stock Price Chart

Key Info

Market Cap 179.76M
Revenue (ttm) 11.37M
Net Income (ttm) -97.67M
Shares Out 62.20M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.89
Previous Close $2.93
Change ($) -0.04
Change (%) -1.37%
Day's Open 2.91
Day's Range 2.81 - 2.94
Day's Volume 287,732
52-Week Range 1.19 - 3.89

More Stats

Market Cap 179.76M
Enterprise Value 86.11M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 62.20M
Float 44.23M
EPS (basic) -1.58
EPS (diluted) -1.60
FCF / Share -1.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.19M
Short Ratio 2.45
Short % of Float 2.39%
Beta 1.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.81
PB Ratio 1.96
Revenue 11.37M
Operating Income -99.64M
Net Income -97.67M
Free Cash Flow -64.34M
Net Cash 93.65M
Net Cash / Share 1.51
Gross Margin -228.47%
Operating Margin -876.46%
Profit Margin -859.20%
FCF Margin -566.00%
ROA -16.69%
ROE -80.63%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(130.80% upside)
Current: $2.89
Target: 6.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth73.49%60.57%-21.19%-47.02%166.39%-7.55%-87.04%178.65%605.6%-
Gross Profit12.527.224.495.7010.764.044.3733.7212.101.72
Operating Income-116-71.61-72.10-77.95-118-58.87-28.62-2.78-24.99-25.30
Net Income-113-69.47-70.98-76.39-117-59.31-36.45-4.41-25.59-25.46
Shares Outstanding55.5048.5946.9646.2743.8833.0019.311.521.501.45
Earnings Per Share-2.03-1.43-1.51-1.65-2.67-1.80-3.65-5.75-23.49-17.52
Operating Cash Flow-75.18-53.73-50.13-63.82-99.71-47.08-25.56-1.88-26.28-21.68
Capital Expenditures-0.16-0.18-0.15-0.84-2.39-1.02-0.19-0.13-0.32-0.12
Free Cash Flow-75.34-53.91-50.28-64.66-102-48.10-25.75-2.00-26.60-21.80
Cash & Equivalents11318715223222023511029.7619.550.00
Total Debt0.
Net Cash / Debt11318615123222023010015.1416.950.00
Book Value11017822227633527598.54-101-93.68-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Chimerix, Inc.
Country United States
Employees 43
CEO Michael A. Sherman

Stock Information

Ticker Symbol CMRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CMRX
IPO Date April 11, 2013


Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.